News Expanded US Imaavy approval first ever for wAIHA The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).
News J&J scores EU approval for Tecvayli combo in second line Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.
News Cavanaugh to replace Taubert as J&J's pharma head Jennifer Taubert will hand over the reins of Johnson & Johnson's Innovative Medicines division to Tom Cavanaugh after she retires on 1st September.
News J&J takes $2.58bn option to buy in vivo CAR-T firm Sail Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.
News Is J&J approaching the end of its talc litigation hangover? Johnson & Johnson has made a $5.5bn bid to finally bring more than 15 years of litigation over the safety of its talcum powder products to a close.
News J&J's oral IL-23 drug backed for psoriasis in EU J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
News Enhertu OK ends 10-year EU gap in frontline breast cancer Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
